Key Points
- SVP Chan Henry Lee sold 341 shares on March 11 at an average price of $300 for $102,300, and had earlier sold 1,660 shares on Feb 4 (avg $349.52) and 664 shares on Jan 7 (avg $331.76).
- BeOne reported quarterly EPS of $0.58, missing estimates of $1.60 while revenue beat slightly at $1.50B versus $1.45B, yet analysts remain largely positive with a consensus "Moderate Buy" and an average target of $401 after several price-target increases.
BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) SVP Chan Henry Lee sold 341 shares of the company's stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $300.00, for a total value of $102,300.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Chan Henry Lee also recently made the following trade(s):
- On Wednesday, February 4th, Chan Henry Lee sold 1,660 shares of BeOne Medicines stock. The shares were sold at an average price of $349.52, for a total value of $580,203.20.
- On Wednesday, January 7th, Chan Henry Lee sold 664 shares of BeOne Medicines stock. The shares were sold at an average price of $331.76, for a total transaction of $220,288.64.
BeOne Medicines Price Performance
ONC stock opened at $284.05 on Friday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.08 and a current ratio of 3.41. The firm has a 50 day moving average price of $334.52 and a 200-day moving average price of $329.55. BeOne Medicines Ltd. - Sponsored ADR has a 52-week low of $196.45 and a 52-week high of $385.22. The firm has a market capitalization of $31.15 billion, a price-to-earnings ratio of 112.72 and a beta of 0.53.
BeOne Medicines (NASDAQ:ONC - Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.58 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.60 by ($1.02). The firm had revenue of $1.50 billion during the quarter, compared to the consensus estimate of $1.45 billion. BeOne Medicines had a return on equity of 10.70% and a net margin of 5.37%. Equities research analysts forecast that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research firms have recently issued reports on ONC. Royal Bank Of Canada raised their price target on BeOne Medicines from $417.00 to $425.00 and gave the stock an "outperform" rating in a research note on Thursday, February 26th. Guggenheim increased their target price on BeOne Medicines from $400.00 to $410.00 and gave the company a "buy" rating in a report on Friday, February 27th. Morgan Stanley reissued an "overweight" rating and issued a $405.00 target price on shares of BeOne Medicines in a research report on Thursday, January 8th. Weiss Ratings restated a "sell (d-)" rating on shares of BeOne Medicines in a research note on Wednesday, January 21st. Finally, Wall Street Zen cut shares of BeOne Medicines from a "strong-buy" rating to a "buy" rating in a research note on Saturday, February 28th. Eleven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $401.00.
View Our Latest Research Report on ONC
Hedge Funds Weigh In On BeOne Medicines
A number of institutional investors have recently bought and sold shares of the stock. EFG International AG purchased a new stake in BeOne Medicines in the fourth quarter worth about $25,000. Anchor Investment Management LLC purchased a new position in shares of BeOne Medicines during the 2nd quarter valued at about $26,000. Leonteq Securities AG purchased a new position in shares of BeOne Medicines during the 4th quarter valued at about $35,000. Daiwa Securities Group Inc. bought a new position in shares of BeOne Medicines during the 2nd quarter valued at approximately $35,000. Finally, CWM LLC increased its holdings in BeOne Medicines by 32.8% in the 4th quarter. CWM LLC now owns 158 shares of the company's stock worth $48,000 after acquiring an additional 39 shares in the last quarter. 48.55% of the stock is owned by institutional investors.
About BeOne Medicines
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
